Back to search results

JoLT-Ca: Sublobar Resection vs. Radiation for Lung Cancer

This study is comparing two treatments for early-stage non-small cell lung cancer: Sublobar Lung Resection (a type of surgery that removes part of the lung) and Stereotactic Ablative Radiotherapy (SAbR), which is a focused type of radiation therapy. The goal is to see if SAbR can improve survival compared to surgery in patients who are considered high-risk for surgery. You might be able to join if you are over 18, have a good performance status (meaning you can do most daily activities), and have lung cancer that looks like non-small cell lung cancer on imaging. The main way they will measure success is by looking at how long people live after 3 years.

Study design
This is an interventional study planning to enroll 272 participants. Patients will be assigned to either Sublobar Lung Resection or Stereotactic Ablative Radiotherapy.
What's involved
Patients will be screened and then assigned to a treatment. You will be followed for at least 2 years after your treatment.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for a minimum of 2 years after treatment, with overall survival measured at 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02468024

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Recruiting
PHASE3Ages 18+InterventionalTreatment
University of Texas Southwestern Medical Center
~272 participants
Updated 2026-04-16 on ClinicalTrials.gov
What's tested:Lung SurgeryRadiation therapy

At a glance

Recruiting sites
12 of 50 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
overall survival
Measured over 3 years

Conditions

Non-Small Cell Lung Cancer

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

50 sites across 32 states
Ohio4
Pennsylvania4
Colorado2
Kentucky2
Maryland2
Michigan2
New York2
North Carolina2

Study leadership

  • Robert Timmerman, MD · PRINCIPAL_INVESTIGATOR · UTSW Medical Center

Who to contact

Sarah Neufeld, MBA
[email protected]
214-645-8525
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

FEV1 ≤ 50% predicted (pre-bronchodilator value)
DLCO ≤ 50% predicted (pre-bronchodilator value)
Study credentialed thoracic surgeon believes the patient is potentially operable but that a lobectomy or pneumonectomy would be poorly tolerated by the patient for tangible or intangible reasons. The belief must be declared and documented in the medical record prior to randomization.
Minor Criteria
Age ≥75
FEV1 51-60% predicted (pre-bronchodilator value)
DLCO 51-60% predicted (pre-bronchodilator value)
Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater than 40mm Hg) as estimated by echocardiography or right heart catheterization
Poor left ventricular function (defined as an ejection fraction of 40% or less)
Resting or Exercise Arterial pO2 ≤ 55 mm Hg or SpO2 ≤ 88%
pCO2 \> 45 mm Hg
Modified Medical Research Council (MMRC) Dyspnea Scale ≥ 3.

What this trial measures

  • overall survival3 years

    To test the hypothesis that the 3-year overall survival in high risk operable patients with Stage I NSCLC is greater in patient who undergo SAbR as compared to standard sublobar resection (SR).